Comments
Loading...

TScan Therapeutics Analyst Ratings

TCRXNASDAQ
Logo brought to you by Benzinga Data
$1.24
-0.07-5.34%
At close: -
$1.25
0.010.81%
After Hours: May 16, 6:25 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$15.00
Lowest Price Target1
$3.00
Consensus Price Target1
$9.86

TScan Therapeutics Analyst Ratings and Price Targets | NASDAQ:TCRX | Benzinga

TScan Therapeutics Inc has a consensus price target of $9.86 based on the ratings of 7 analysts. The high is $15 issued by HC Wainwright & Co. on March 6, 2025. The low is $3 issued by Barclays on March 7, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Needham, and Morgan Stanley on May 7, 2025, April 8, 2025, and March 14, 2025, respectively. With an average price target of $9.67 between HC Wainwright & Co., Needham, and Morgan Stanley, there's an implied 673.33% upside for TScan Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Dec 24
4
Mar
1
Apr
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Needham
Morgan Stanley
Barclays
HC Wainwright & Co.

1calculated from analyst ratings

Analyst Ratings for TScan Therapeutics

Buy NowGet Alert
05/07/2025Buy Now700%HC Wainwright & Co.
Andres Maldonado42%
$15 → $10MaintainsBuyGet Alert
04/08/2025Buy Now620%Needham
Gil Blum49%
$9 → $9ReiteratesBuy → BuyGet Alert
03/14/2025Buy Now700%Morgan Stanley
Maxwell Skor21%
→ $10Assumes → OverweightGet Alert
03/07/2025Buy Now140%Barclays
Peter Lawson42%
$14 → $3MaintainsOverweightGet Alert
03/06/2025Buy Now1100%HC Wainwright & Co.
Andrew Fein55%
$15 → $15ReiteratesBuy → BuyGet Alert
03/05/2025Buy Now620%Needham
Gil Blum49%
$11 → $9MaintainsBuyGet Alert
12/11/2024Buy Now1100%HC Wainwright & Co.
Andrew Fein55%
$15 → $15ReiteratesBuy → BuyGet Alert
12/11/2024Buy Now780%Needham
Gil Blum49%
$11 → $11ReiteratesBuy → BuyGet Alert
11/15/2024Buy Now1100%HC Wainwright & Co.
Andrew Fein55%
$15 → $15ReiteratesBuy → BuyGet Alert
11/12/2024Buy Now780%Needham
Gil Blum49%
$11 → $11ReiteratesBuy → BuyGet Alert
11/06/2024Buy Now780%Needham
Gil Blum49%
$11 → $11ReiteratesBuy → BuyGet Alert
08/13/2024Buy Now700%Wedbush
David Nierengarten57%
$10 → $10ReiteratesOutperform → OutperformGet Alert
08/13/2024Buy Now1100%HC Wainwright & Co.
Andrew Fein55%
$15 → $15ReiteratesBuy → BuyGet Alert
08/12/2024Buy Now780%Needham
Gil Blum49%
$11 → $11ReiteratesBuy → BuyGet Alert
06/04/2024Buy Now1100%HC Wainwright & Co.
Andrew Fein55%
$15 → $15ReiteratesBuy → BuyGet Alert
05/16/2024Buy Now860%BTIG
Justin Zelin39%
→ $12Initiates → BuyGet Alert
05/14/2024Buy Now1100%HC Wainwright & Co.
Andrew Fein55%
$15 → $15ReiteratesBuy → BuyGet Alert
05/13/2024Buy Now780%Needham
Gil Blum49%
→ $11ReiteratesBuy → BuyGet Alert
04/23/2024Buy Now700%Wedbush
David Nierengarten57%
$10 → $10ReiteratesOutperform → OutperformGet Alert
03/07/2024Buy Now1100%HC Wainwright & Co.
Andrew Fein55%
$15 → $15ReiteratesBuy → BuyGet Alert
03/07/2024Buy Now620%Barclays
Peter Lawson42%
$7 → $9MaintainsOverweightGet Alert
02/01/2024Buy Now620%Wedbush
David Nierengarten57%
$9 → $9ReiteratesOutperform → OutperformGet Alert
08/14/2023Buy Now1100%HC Wainwright & Co.
Andrew Fein55%
→ $15ReiteratesBuy → BuyGet Alert
06/22/2023Buy Now540%Wedbush
David Nierengarten57%
→ $8Initiates → OutperformGet Alert
05/18/2023Buy Now1100%HC Wainwright & Co.
Andrew Fein55%
→ $15ReiteratesBuy → BuyGet Alert
05/11/2023Buy Now1100%HC Wainwright & Co.
Andrew Fein55%
→ $15ReiteratesBuy → BuyGet Alert
03/09/2023Buy Now1100%HC Wainwright & Co.
Andrew Fein55%
→ $15Reiterates → BuyGet Alert

FAQ

Q

What is the target price for TScan Therapeutics (TCRX) stock?

A

The latest price target for TScan Therapeutics (NASDAQ:TCRX) was reported by HC Wainwright & Co. on May 7, 2025. The analyst firm set a price target for $10.00 expecting TCRX to rise to within 12 months (a possible 700.00% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for TScan Therapeutics (TCRX)?

A

The latest analyst rating for TScan Therapeutics (NASDAQ:TCRX) was provided by HC Wainwright & Co., and TScan Therapeutics maintained their buy rating.

Q

When was the last upgrade for TScan Therapeutics (TCRX)?

A

There is no last upgrade for TScan Therapeutics

Q

When was the last downgrade for TScan Therapeutics (TCRX)?

A

There is no last downgrade for TScan Therapeutics.

Q

When is the next analyst rating going to be posted or updated for TScan Therapeutics (TCRX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TScan Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TScan Therapeutics was filed on May 7, 2025 so you should expect the next rating to be made available sometime around May 7, 2026.

Q

Is the Analyst Rating TScan Therapeutics (TCRX) correct?

A

While ratings are subjective and will change, the latest TScan Therapeutics (TCRX) rating was a maintained with a price target of $15.00 to $10.00. The current price TScan Therapeutics (TCRX) is trading at is $1.25, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch